Menopause and Ozempic (GLP-1): what the science really says

What you will understand

You are careful, you move, and yet since menopause the weight no longer goes down and the belly settles in. Around you, everyone is talking about Ozempic and Wegovy. This video looks without a filter at what the science really says about GLP-1s at menopause.

It examines what the major trials show (STEP for semaglutide, SURMOUNT for tirzepatide) about real effectiveness, and above all who these treatments are for. An important point: GLP-1s are not approved to treat menopause. They are drugs for obesity and diabetes, with precise indications.

The video then insists on a risk that is very specific to this period of life and rarely explained: a significant share of the weight lost on GLP-1s is lean mass. Yet at menopause, muscle mass and bone density are already declining. Losing weight without protecting muscle and bone amounts to solving one problem while worsening another, hence the importance of protein and strength training alongside.

What the studies show

First thing to establish: what these drugs really are. GLP-1 is a hormone the gut makes at mealtimes. It alerts the pancreas, slows stomach emptying and tells the brain that the meal is under way. Semaglutide and tirzepatide are modified copies of this hormone, designed to last several days instead of a few minutes. They burn nothing and speed up no metabolism: they make satiety come earlier and last longer, and they dampen what researchers call food noise.

Next, why menopause changes the picture. The drop in estrogen changes where fat is deposited: it leaves the hips and thighs for the abdomen, including around the organs. In parallel, muscle mass declines. A review devoted to managing obesity at menopause describes precisely this double mechanism. That is what explains a very common experience: the weight barely moves, and yet clothes no longer fit the same way.

What do the trials say? The major reference trials, STEP for semaglutide and SURMOUNT for tirzepatide, document substantial weight loss, but in populations defined by criteria of obesity or diabetes. The specifically menopausal literature is still thin, and that is an honest limit to state: most of these trials included women without analyzing separately those who were in perimenopause or beyond. One study evaluated low doses of semaglutide in menopausal women while measuring body composition, and two recent reviews take stock of this population.

The point of vigilance is muscle, and it is specific to this age. Any rapid weight loss comes with a loss of lean mass: that is true of a restrictive diet as of surgery. What is specific to the fifties is that the muscle capital is already declining and that bone is losing density. The body composition analysis of the STEP 1 trial documented this share of lean mass in the weight lost. Sufficient protein intake and regular strength training are therefore not an optional extra: they are part of the management.

Two practical questions come up often. First, hormone therapy: an analysis compared the weight response to semaglutide in menopausal women according to whether or not they were taking hormone therapy, which does not amount to a recommendation but justifies the doctor having both pieces of information in hand. Second, contraception: in perimenopause, pregnancy remains possible, and the study that tested the question concludes that semaglutide does not reduce the bioavailability of a combined ethinylestradiol and levonorgestrel pill. That result concerns one molecule and one precise combination, not all combinations.

Finally, what these drugs do not solve: neither hot flashes, nor sleep, nor dryness, nor mood. The most frequent adverse effects are digestive, nausea, slowed transit, reflux, and they depend a great deal on the pace of dose increases. And stopping raises a real question, since weight frequently comes back, which pushes toward thinking of these treatments as long-term rather than as a course.

All these references appear with their PubMed identifiers in the written and sourced version of this topic.

The key points to remember

• GLP-1s are NOT approved to treat menopause: they are drugs for obesity and diabetes.
• The STEP and SURMOUNT trials document substantial weight loss, but in precise populations.
• A notable share of the weight lost is lean mass, a major issue when you are already losing muscle with age.
• Sufficient protein and strength training are not optional if a GLP-1 is prescribed: they protect muscle and bone.
• Prescription, follow-up and stopping are a medical decision, never an online purchase.
• These molecules burn nothing: they mimic a gut hormone that brings satiety forward and prolongs it.
• Data specific to menopausal women remain limited: that is an honest limit to know before any figure.
• They act neither on hot flashes, nor on sleep, nor on dryness, nor on mood.
• The most frequent adverse effects are digestive and depend on the pace of dose increases.
• Weight frequently comes back after stopping, which pushes toward thinking of these treatments as long-term rather than as a course.

Video chapters

1. 0:00 The real problem
2. 1:32 Why your body changes at menopause
3. 3:08 What the science really says (STEP, SURMOUNT)
4. 5:50 The risk no one tells you about (muscle + bone)
5. 8:29 The right way to do it
6. 9:23 The mistakes to avoid
7. 11:03 Your checklist

The scientific sources cited

Every claim in this video rests on a verified reference. Here is the complete list, with the PubMed links.

• Wilding JPH, et al. Once-Weekly Semaglutide in Overweight or Obesity (STEP 1). N Engl J Med. 2021. PubMed 33567185
• Jastreboff AM, et al. Tirzepatide Once Weekly for Obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
• Wilding JPH, et al. Impact of Semaglutide on Body Composition (STEP 1, DXA). J Endocr Soc. 2021. PMC8089287
• Liu H, et al. Weight loss induced bone loss. Bone Res. 2025. PubMed 41326347
• Kodoth V, et al. Body Composition During the Menopausal Transition. Womens Health Rep. 2022. PubMed 35814604
• Rubino D, et al. Continued vs withdrawn semaglutide (STEP 4). JAMA. 2021. PubMed 33755728
• Graczyk NA, Bisschops J. GLP-1RAs for Obesity and Symptoms in Menopause (review). Cureus. 2026. PubMed 41704988
• Bettge K, et al. GI adverse events of GLP-1RAs. Diabetes Obes Metab. 2017. PubMed 27860132

Frequently asked questions